The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer
Open accessAbstract
// Francesco Crea 1 , Akira Watahiki 1,2 , Luca Quagliata 3 , Hui Xue 1 , Larissa Pikor 4 , Abhijit Parolia 1,5 , Yuwei Wang 1 , Dong Lin 1,2 , Wan L. Lam 4 , William L. Farrar 6 , Takao Isogai 7 , Rudolf Morant 8 , Serenella Castori-Eppenberger 3 , Kim N. Chi 2,9 , Yuzhuo Wang 1,2 , and Cheryl D. Helgason 1 1 Experimental Therapeutics, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada. 2 The Vancouver prostate Centre, Vancouver General Hospital, Vancouver BC, Canada. 3 Molecular Pathology Unit, Institute of Pathology, University Hospital Basel, Switzerland 4 Genetics Unit, Integrative Oncology, BC Cancer Agency Cancer Research Centre, Vancouver BC, Canada. 5 Honours Biotechnology, Department of Microbiology and Immunology, University of British Columbia, Vancouver BC, Canada 6 Cancer Stem Cell Section, National Laboratory at Frederick, MD, USA. 7 Translational Research Center, Fukushima Medical University, Fukushima, Japan 8 Cancer Center, ZeTuP AG St.Gallen, St.Gallen, Switzerland 9 Medical Oncology, BC Cancer Agency Vancouver Cancer Centre, Vancouver BC, Canada. Correspondence: Cheryl D. Helgason, email: // Francesco Crea, email: // Keywords : long non-coding RNA, prostate cancer, metastasis, androgen receptor, cancer biomarkers. Received : January 15, 2014 Accepted : February 4, 2014 Published : February 6, 2014 Abstract Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets. We therefore performed RNA sequencing on paired metastatic/non-metastatic PCa xenografts derived from clinical specimens. The most highly up-regulated transcript was LOC728606, a lncRNA now designated PCAT18. PCAT18 is specifically expressed in the prostate compared to 11 other normal tissues (p<0.05) and up-regulated in PCa compared to 15 other neoplasms (p<0.001). Cancer-specific up-regulation of PCAT18 was confirmed on an independent dataset of PCa and benign prostatic hyperplasia samples (p<0.001). PCAT18 was detectable in plasma samples and increased incrementally from healthy individuals to those with localized and metastatic PCa (p<0.01). We identified a PCAT18-associated expression signature (PES), which is highly PCa-specific and activated in metastatic vs. primary PCa samples (p<1E -4 , odds ratio>2). The PES was significantly associated with androgen receptor (AR) signalling. Accordingly, AR activation dramatically up-regulated PCAT18 expression in vitro and in vivo. PCAT18 silencing significantly (p<0.001) inhibited PCa cell proliferation and triggered caspase 3/7 activation, with no effect on non-neoplastic cells. PCAT18 silencing also inhibited PCa cell migration (p<0.01) and invasion (p<0.01). These results position PCAT18 as a potential therapeutic target and biomarker for metastatic PCa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Complete sequencing and characterization of 21,243 full-length human cDNAs
Ota, T., Suzuki, Y., Nishikawa, T., Otsuki, T., Sugiyama, T., Irie, R., Wakamatsu, A., Hayashi, K., Sato, H., Nagai, K., et al. (2004) · Nature Genetics · doi:10.1038/ng1285 · Cited by 925
Self-citationPepBank - a database of peptides based on sequence text mining and public peptide data sources.
Shtatland, T., Guettler, D., Kossodo, M., Pivovarov, M., & Weissleder, R. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-280 · Cited by 181
Cited by
Long Noncoding RNA and Cancer: A New Paradigm
Bhan, A., Soleimani, M., & Mandal, S. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2634 · Cited by 2,861
Clinical utility of circulating non-coding RNAs — an update
Anfossi, S., Babayan, A., Pantel, K., & Calin, G. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0035-x · Cited by 450
Long Noncoding RNAs as Biomarkers in Cancer
Bolha, L., Ravnik-Glavač, M., & Glavač, D. (2017) · Disease Markers · doi:10.1155/2017/7243968 · Cited by 365
Liquid biopsy: a step forward towards precision medicine in urologic malignancies
Di Meo, A., Bartlett, J., Cheng, Y., Pasic, M. D., & Yousef, G. M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0644-5 · Cited by 330
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19
Hua, J. T., Ahmed, M., Guo, H., Zhang, Y., Chen, S., Soares, F., Lu, J., Zhou, S., Wang, M., Li, H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.014 · Cited by 315
Metadata
- Authors
- Crea, F., Watahiki, A., Quagliata, L., Xue, H., Pikor, L., Parolia, A., Wang, Y., Lin, D., Lam, W. L., Farrar, W. L., Isogai, T., Morant, R., Castori-Eppenberger, S., Chi, K. N., Wang, Y., & Helgason, C. D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-02-06
- Volume
- 5
- Issue
- 3
- Pages
- 764-774
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1897003648
- Cited by
- 220
- References
- 4
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. https://app.cochat.ai/papers/10.18632/oncotarget.1769
- The paper
- Crea, F., Watahiki, A., Quagliata, L., Xue, H., Pikor, L., Parolia, A., Wang, Y., Lin, D., Lam, W. L., Farrar, W. L., Isogai, T., Morant, R., Castori-Eppenberger, S., Chi, K. N., Wang, Y., & Helgason, C. D. (2014). Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget. https://doi.org/10.18632/oncotarget.1769
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.